A-6880 17-AAG, >99%

Prices_reduced
  • Size
  • US $
  • £
  • ¥
  • 25 mg
  • 39
  • 36
  • 31
  • 4,300
  • Add to Cart
  • Out of stock
  • 100 mg
  • 79
  • 73
  • 63
  • 8,800
  • Add to Cart
  • Out of stock
  • 200 mg
  • 142
  • 132
  • 114
  • 15,800
  • Add to Cart
  • Out of stock
  • 250 mg
  • 168
  • 156
  • 135
  • 18,600
  • Add to Cart
  • Out of stock
  • 500 mg
  • 228
  • 212
  • 183
  • 25,300
  • Add to Cart
  • Out of stock
  • 1 g
  • 391
  • 363
  • 314
  • 43,400
  • Add to Cart
  • Out of stock
  • 2 g
  • 670
  • 623
  • 539
  • 74,400
  • Add to Cart
  • Out of stock
  • 5 g
  • 1,090
  • 1,013
  • 877
  • 121,000
  • Add to Cart
  • Out of stock
  • 10 g
  • 1,740
  • 1,618
  • 1,400
  • 193,100
  • Add to Cart
  • Out of stock

Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.

To receive a Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities Click Here to see what Shipping and Handling Costs would be to Your Country
  • M.W. 585.69
  • C31H43N3O8
  • [75747-14-7]

Warnings: Toxic.

Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 150 mg/mL; soluble in ethanol at 5 mg/mL; very poorly soluble in water; maximum solubility in plain water is estimated to be about 20-50 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A.

  • Semi-synthetic derivative of geldanamycin, Cat. No. G-4500, demonstrating greater stability and lower in vivo toxicity than its parent compound. 17-AAG binds specifically to heat shock protein Hsp90 in a manner similar to geldanamycin, but the binding is weaker. Schulte, T.W. and Neckers, L.M. "The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin." Cancer Chemother. Pharmacol. 42: 273-279 (1998).
  • Inhibits Akt activation and HER2 expression in tumor cells. Basso, A.D., et al. "Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2." Oncogene 21: 1159-1166 (2002).
  • Exhibits 100-fold higher binding affinity for tumor-cell-derived hsp90 over that derived from normal cells. Kamal, A., et al. "A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors." Nature 425: 407-10 (2003).
  • Sensitizes tumor cells to growth arrest and apoptosis induced by paclitaxel, Cat. No. P-9600. Nguyen, D.M., et al. "Sequence-dependent enhancement of paclitaxel toxicity in non-small cell lung cancer by 17-allylamino 17-demethoxygeldanamycin." J. Thorac. Cardiovasc. Surg. 118: 908-915 (1999) and Solit, D.B., et al. "Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol." Cancer Res. 63: 2139-2144 (2003).
  • Sensitizes colon cancer cells to cisplatin-induced cell death. Vasilevskaya, I.A., et al. "Quantitative effects on c-Jun N-terminal protein kinase signaling determine synergistic interaction of cisplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines." Mol Pharmacol. 65: 235-243 (2004).
  • Inhibits angiogenesis. Kaur, G, et al. "Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator." Clin. Cancer Res. 10: 4813-4821 (2004).
  • Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use.
1272